Umbilical Cord-derived Mesenchymal Stem Cells for Ischemic Stroke

Korábbi kezelés

• Patients receiving intravenous thrombolysis;

Más betegség

• Intracranial hemorrhagic diseases: cerebral hemorrhage, subarachnoid hemorrhage, etc;
• Epilepsy patients;
• Severe neurological deficit caused by stroke (MRS = 5);
• Previous diseases with obvious functional impairment, such as Parkinson's disease, motor neuron disease, moderate Alzheimer's disease, osteoarthritis, etc;
• Patients with history of coagulation disorders, systemic bleeding tendency and thrombocytopenia (< 100000 / mm3);
• Patients with moderate to severe mental illness obviously interfere with treatment compliance;

Laborértékek

• Chronic liver disease, liver and kidney dysfunction, elevated ALT or ast (2 times higher than the upper limit of normal value), elevated serum creatinine (1.5 times higher than the upper limit of normal value) or dependent on renal dialysis;

Életkor

• Pregnant women or women of childbearing age who have not taken effective contraceptive measures;

Egyéb

• Patients who need or expect decompressive craniectomy;
• Patients who need or are expected to receive endovascular treatment ;
• Disturbance of consciousness；
• Posterior circulation cerebral infarction;
• Tumor patients;
• Patients with high blood pressure (systolic blood pressure > 180mmhg) or low blood pressure (systolic blood pressure < 90mmHg);
• The expected survival time is less than one year;
• Those who have conducted other trials within 3 months;
• Other circumstances considered unsuitable by the researcher.

• Age: 18-80 years old;
• Patients with anterior circulation cerebral infarction;
• NIHSS: 6-25, and the limb movement score is at least 2 points;
• Hemoglobin > 115g / L, platelet > 100 × 109 / L, leukocyte > 3 × 109 / L;
• the time from onset to treatment: group A（6-24 hours）、group B（1-3 days）、gourp C（4-7 days）、group D（1-4 weeks）、group E（1-6 months）;
• The patient or the legal representative of the patient can and is willing to sign the informed consent.